19Mar 2025
CBX3 Drives Chemoresistance in CRC by Inhibiting Ferroptosis via NRF2

CBX3 Drives Chemoresistance in CRC by Inhibiting Ferroptosis via NRF2

The study revealed that CBX3 overexpression worsens patient survival and increases resistance to Irinotecan and Oxaliplatin. CBX3 inhibits ferroptosis via the NRF2 pathway by suppressing CUL3-mediated NRF2 degradation, with GPX2 as a key downstream target. NRF2 inhibitor ML385 restores ferroptosis and overcomes chemoresistance in PDX models, highlighting the CBX3/NRF2/GPX2 axis as a promising therapeutic target.

  • #oncology

Like

Save

Share